Skip to main content
Autobound logo

What Moderna's latest 10-Q says: 12 signals

Moderna filed its latest 10-Q with the SEC on Jul 31, 2026. It discusses AI investment, capex increase and cash flow concern.

Public (MRNA)Biotechnology Research5,001 to 10,000 employeesmodernatx.comLinkedIn

Filed
Jul 31, 2026
Filings
2
Signals
24

10-Q · latest 10

What Moderna's 10-Q filings say

  1. 10-Q

    Filed · 12 signals

    SEC EDGAR

  2. 10-Q

    Filed · 12 signals

    SEC EDGAR

Showing 10 of 24 filing signals. The Signal API returns all of them.

Get them with one API call

Earnings calls

Moderna earnings headlines

From earnings call transcripts (Signal API type earnings-transcripts).

Earnings call headlines
Call dateWhat the company said
Actively deploying 'large number of GPTs' to drive productivity and cut costs.The CEO explicitly stated the company is using numerous GPTs and other digital tools as a core part of its successful cost reduction and productivity strategy. This indicates an active budget and appetite for AI-based solutions that can deliver operational efficiency.
Aggressively cutting $900M from 2025 cash costs, targeting 50% reduction by 2025The company has an intense, top-down focus on financial discipline and cost reduction, having already cut $900M from its 2025 cash cost plan. This creates significant opportunities for vendors offering efficiency solutions, cost optimization services, or more favorable pricing.
Deferring major Phase III R&D investments to conserve cash until 2028The company is strategically pausing advancement of promising but expensive late-stage clinical programs (like its EBV vaccine) to meet its cash breakeven target. This R&D pipeline restructuring indicates a need for solutions that improve clinical trial efficiency and reduce R&D costs.
Actively seeking "better pricing with our suppliers across the entire company"The CEO has signaled a company-wide initiative to secure better pricing from all suppliers as part of its aggressive cost-cutting program. This makes the company highly receptive to new vendors who can offer more competitive pricing or a better total cost of ownership.
Shifting clinical trial focus from speed to cost-efficiency, creating tech needs.The CFO noted a strategic shift in clinical trial execution to prioritize cost and efficiency over pure speed. This change opens opportunities for vendors of clinical trial management systems (CTMS), data analytics platforms, and other technologies that can optimize trial costs and processes.
Announced capital expenditure budget of approximately $300 million for 2025.The company has allocated approximately $300 million for capital expenditures in 2025. This budget is designated for investments in infrastructure, facilities, and equipment, presenting a clear opportunity for relevant suppliers.

Signal API · MCP

Track Moderna with the Signal API

One POST /v1/companies/enrich call with modernatx.com returns Moderna 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.

Start Free1,000 free creditsUse it in Claude via MCP

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"modernatx.com","signal_types":["sec-10q"],"limit":20}'

Same industry

10-Q at related companies

Questions about Moderna 10-Q

When did Moderna file its latest 10-Q?
Moderna filed its latest 10-Q on Jul 31, 2026. The one before it was filed on May 1, 2026.
What did Moderna disclose in its latest 10-Q?
From the filing dated Jul 31, 2026: Moderna faces new patent infringement lawsuit from Sanofi over COVID and RSV vaccines.
What did Moderna say on its recent earnings calls?
Q3 FY2025: Actively deploying 'large number of GPTs' to drive productivity and cut costs. (dated Nov 6, 2025).
Where can I read Moderna's 10-Q filing?
The full filing is on SEC EDGAR: https://www.sec.gov/Archives/edgar/data/1682852/000168285226000150/mrna-20260630.htm. This page summarizes what the filing says and links to it.

Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.

Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.

Data as of .

How this data is built →Get it from the Signal API →